Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05736523 · ClinicalTrials.gov registry record

Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)

A clinical trial of Melanoma, sponsored by University of Utah.

Active
Registry status
28
Enrollment target
2
Study locations

NCT05736523: Active study of Melanoma, sponsored by University of Utah.

NCT05736523 is a study of Melanoma that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 28 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05736523, a study of Melanoma, is active but no longer recruiting, sponsored by University of Utah.

ACTIVE NOT RECRUITING
Registry status
28 participants
Enrollment target
2
Study locations

Study Summary

This is a non-randomized experimental biomarker study evaluating ctDNA levels in patients with stage IIB/C and stage IIIB/C/D melanoma skin cancer pre and post-surgery Study participants will complete a ctDNA test within 4 weeks of their planned surgical resection of their melanoma. Within 4 weeks post-surgery another ctDNA test will be completed. During these time points stool samples and diet questionnaires will be collected for biospecimen banking.

Primary Outcome

The proportion of cases in which sample acquisition, processing and return of results from the two initial ctDNA (serum VAF allele levels, ng/ml) analyses occurs within 6 weeks of acquisition of the post-operative serum sample. The two ctDNA analyses are from the initial tumor biopsy and blood, and post-operative blood draw.

Conditions Studied

Melanoma

Study Locations (2)

Utah

  • Intermountain Medical Center - Murray
  • Huntsman Cancer Institute - Salt Lake City

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2020-09-23
Est. Completion 2025-06
University of Utah

818 total trials

What the registry record for NCT05736523 still lists

NCT05736523 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 0 interventions.

NCT05736523 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT05736523 about?

NCT05736523 is a clinical study titled "Improving Early Detection of Melanoma Recurrence With Circulating Tumor DNA (ctDNA)". This is a non-randomized experimental biomarker study evaluating ctDNA levels in patients with stage IIB/C and stage IIIB/C/D melanoma skin cancer pre and post-surgery Study participants will complete a ctDNA test within 4 weeks of their planned surgical resection of their melanoma. Within 4 weeks ...

What is the current status of trial NCT05736523?

This trial is currently active not recruiting. The enrollment target is 28 participants. The study started on 2020-09-23. Estimated completion is 2025-06.

What conditions does trial NCT05736523 study?

This clinical trial studies the following conditions: Melanoma.

Who is sponsoring clinical trial NCT05736523?

This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05736523 being conducted?

This trial has 2 study locations across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05736523's enrollment target sits among peer trials

28 207th of 266 higher than 58 of 266 other Melanoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT05736523, the US trial registry maintained by the National Library of Medicine. NCT05736523 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.